loading
Precedente Chiudi:
$12.01
Aprire:
$12.13
Volume 24 ore:
68,153
Relative Volume:
0.13
Capitalizzazione di mercato:
$594.10M
Reddito:
-
Utile/perdita netta:
$-156.39M
Rapporto P/E:
-3.2873
EPS:
-3.69
Flusso di cassa netto:
$-123.06M
1 W Prestazione:
+0.83%
1M Prestazione:
+1.93%
6M Prestazione:
-1.86%
1 anno Prestazione:
+5.94%
Intervallo 1D:
Value
$12.11
$12.52
Intervallo di 1 settimana:
Value
$11.42
$12.82
Portata 52W:
Value
$7.30
$15.50

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Name
Nome
Kalvista Pharmaceuticals Inc
Name
Telefono
(857) 999-0075
Name
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Dipendente
0
Name
Cinguettio
@kalvista
Name
Prossima data di guadagno
2025-03-12
Name
Ultimi documenti SEC
Name
KALV's Discussions on Twitter

Confronta KALV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
KALV
Kalvista Pharmaceuticals Inc
12.19 594.10M 0 -156.39M -123.06M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.08 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
577.44 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.32 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.66 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.34 26.16B 3.81B -644.79M -669.77M -6.24

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-31 Iniziato JMP Securities Mkt Outperform
2025-01-07 Iniziato TD Cowen Buy
2024-12-18 Iniziato BofA Securities Buy
2020-06-15 Iniziato H.C. Wainwright Buy
2019-07-29 Iniziato SVB Leerink Outperform
2019-03-20 Iniziato Needham Buy
2018-10-30 Iniziato Jefferies Buy
2018-09-21 Iniziato Cantor Fitzgerald Overweight
2017-08-31 Iniziato BTIG Research Buy
Mostra tutto

Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie

pulisher
03:43 AM

Russell Investments Group Ltd. Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

03:43 AM
pulisher
Apr 19, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform - insights.citeline.com

Apr 18, 2025
pulisher
Apr 17, 2025

(KALV) Trading Report - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 17, 2025

Vanguard Group Inc. Acquires 104,716 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Apr 17, 2025
pulisher
Apr 15, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc. - Defense World

Apr 15, 2025
pulisher
Apr 15, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Corebridge Financial Inc. - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Wellington Management Group LLP Has $1.04 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

KalVista Pharmaceuticals’ Licensing Agreement with Kaken Pharmaceutical - Global Legal Chronicle

Apr 13, 2025
pulisher
Apr 13, 2025

The week in pharma: action, reaction and insight – week to April 11 - The Pharma Letter

Apr 13, 2025
pulisher
Apr 12, 2025

KalVista: Poised For Rare Disease Transformation - Seeking Alpha

Apr 12, 2025
pulisher
Apr 10, 2025

Kaken, Kalvista partner on HAE treatment sebetralstat in Japan - Angioedema News

Apr 10, 2025
pulisher
Apr 09, 2025

KalVista licensing deal with Kaken - The Pharma Letter

Apr 09, 2025
pulisher
Apr 09, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Given “Buy” Rating at Needham & Company LLC - Defense World

Apr 09, 2025
pulisher
Apr 08, 2025

KalVista inks Japan licensing deal for HAE drug sebetralstat - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista inks Japan licensing deal for HAE drug sebetralstat By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista licenses commercialisation rights for HAE to Kaken in Japan - Yahoo

Apr 08, 2025
pulisher
Apr 08, 2025

Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista licences HAE therapy commercialisation rights to Kaken - Pharmaceutical Technology

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista Pharmaceuticals Signs Agreement with Kaken Pharmaceutical - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - BioSpace

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista stock rises on licensing deal in Japan (KALV:NASDAQ) - Seeking Alpha

Apr 08, 2025
pulisher
Apr 08, 2025

Kalvista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical To Commercialize Sebetralstat For HAE In Japan - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista Pharmaceuticals, Inc. Enters into Licensing Agreement with Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Humana (HUM) and PROCEPT BioRobotics (PRCT) - The Globe and Mail

Apr 08, 2025
pulisher
Apr 05, 2025

Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Hereditary Angioedema Pipeline: Over 20 Leading Companies - openPR.com

Apr 04, 2025
pulisher
Apr 03, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace

Apr 03, 2025
pulisher
Apr 01, 2025

Where are the Opportunities in (KALV) - news.stocktradersdaily.com

Apr 01, 2025
pulisher
Mar 31, 2025

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph

Mar 31, 2025
pulisher
Mar 31, 2025

Charles Schwab Investment Management Inc. Sells 10,372 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Mar 31, 2025
pulisher
Mar 29, 2025

Q4 Earnings Estimate for KALV Issued By Leerink Partnrs - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Earns Buy Rating from Needham & Company LLC - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

KONFIDENT-KID trial of sebetralstat is now fully enrolled - Angioedema News

Mar 27, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Kalvista shares By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Buy on Kalvista stock, price target steady at $39 By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Buy on Kalvista stock, price target steady at $39 - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Kalvista shares - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Kalvista stock holds as JMP reiterates $19 target By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Bank of New York Mellon Corp - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Kalvista stock holds as JMP reiterates $19 target - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

KalVista completes enrollment for pediatric HAE trial By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

KalVista completes enrollment for pediatric HAE trial - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial - MarketScreener

Mar 25, 2025

Kalvista Pharmaceuticals Inc Azioni (KALV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
Capitalizzazione:     |  Volume (24 ore):